Verastem Inc  

(Public, NASDAQ:VSTM)   Watch this stock  
Find more results for VSTM
1.42
-0.14 (-8.97%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.40 - 1.53
52 week 1.05 - 8.99
Open 1.53
Vol / Avg. 449,874.00/476,309.00
Mkt cap 52.19M
P/E     -
Div/yield     -
EPS -1.39
Shares 36.99M
Beta 2.16
Inst. own 46%
Aug 8, 2016
Q2 2016 Verastem Inc Earnings Release (Estimated) Add to calendar
May 9, 2016
Q1 2016 Verastem Inc Earnings Release
Mar 15, 2016
Verastem Inc at ROTH Conference
Mar 3, 2016
Q4 2015 Verastem Inc Earnings Call - Webcast
Mar 3, 2016
Q4 2015 Verastem Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -30.85% -54.66%
Return on average equity -33.53% -60.52%
Employees 22 -
CDP Score - -

Address

117 Kendrick St Ste 500
NEEDHAM, MA 02494-2730
United States - Map
+1-781-2924200 (Phone)
+1-914-9499618 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Officers and directors

Christoph H. Westphal Ph.D. Executive Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Robert Forrester President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Joe Chiapponi Principal Financial Officer, Principal Accounting Officer, Treasurer
Age: 47
Bio & Compensation  - Reuters
Daniel W. Paterson Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Monica Kleinman Vice President, General Counsel
Age: 34
Bio & Compensation  - Reuters
Gregory I. Berk M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Henri A. Termeer Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Timothy Joseph Barberich Independent Director
Age: 67
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Michael G. Kauffman M.D., Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters